Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

M Cavo; F Gay; M Beksac; L Pantani; MT Petrucci; MA Dimopoulos; L Dozza; Ronnie van der Holt; S Zweegman; S Oliva; Vincent van der Velden; E Zamagni; GA Palumbo; F Patriarca; V Montefusco; M Galli; V Maisnar; B Gamberi; M Hansson; A Belotti; L Pour; P Ypma; M Grasso; A Croockewit; S Ballanti; M Offidani; ID Vincelli; R Zambello; AM Liberati; NF Andersen; A. Broijl; R Troia; A Pascarella; G Benevolo; MD Levin; G Bos; H Ludwig; S Aquino; AM Morelli; KL Wu; R Boersma; R Hajek; M Durian; Pavd von dem Borne; T Caravita di Toritto; T Zander; G Specchia; A Waage; P Gimsing; UH Mellqvist; M van Marwijk Kooy; M Minnema; C Mandigers; AM Cafro; A Palmas; S Carvalho; A Spencer; M Boccadoro; Pieter Sonneveld

doi:10.1016/s2352-3026(20)30099-5

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, L Dozza, Ronnie van der Holt, S Zweegman, S Oliva, Vincent van der Velden, E Zamagni, GA Palumbo, F Patriarca, V Montefusco, M Galli, V Maisnar, B Gamberi, M Hansson, A BelottiL Pour, P Ypma, M Grasso, A Croockewit, S Ballanti, M Offidani, ID Vincelli, R Zambello, AM Liberati, NF Andersen, A. Broijl, R Troia, A Pascarella, G Benevolo, MD Levin, G Bos, H Ludwig, S Aquino, AM Morelli, KL Wu, R Boersma, R Hajek, M Durian, Pavd von dem Borne, T Caravita di Toritto, T Zander, G Specchia, A Waage, P Gimsing, UH Mellqvist, M van Marwijk Kooy, M Minnema, C Mandigers, AM Cafro, A Palmas, S Carvalho, A Spencer, M Boccadoro, Pieter Sonneveld

Research output: Contribution to journal › Article › Academic › peer-review

195 Citations (Scopus)

Original language	English
Pages (from-to)	E456-E468
Journal	The Lancet Haematology
Volume	7
Issue number	6
DOIs	https://doi.org/10.1016/s2352-3026(20)30099-5 https://doi.org/10.1016/S2352-3026(20)30099-5
Publication status	Published - 1 Jun 2020

Access to Document

http://hdl.handle.net/1765/128395

Cite this

Cavo, M., Gay, F., Beksac, M., Pantani, L., Petrucci, MT., Dimopoulos, MA., Dozza, L., van der Holt, R., Zweegman, S., Oliva, S., van der Velden, V., Zamagni, E., Palumbo, GA., Patriarca, F., Montefusco, V., Galli, M., Maisnar, V., Gamberi, B., Hansson, M., ... Sonneveld, P. (2020). Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. The Lancet Haematology, 7(6), E456-E468. https://doi.org/10.1016/s2352-3026(20)30099-5, https://doi.org/10.1016/S2352-3026(20)30099-5

Cavo, M ; Gay, F ; Beksac, M et al. / Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95) : a multicentre, randomised, open-label, phase 3 study. In: The Lancet Haematology. 2020 ; Vol. 7, No. 6. pp. E456-E468.

@article{8d23c5ae42be478bbc1871a406d911c5,

title = "Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study",

author = "M Cavo and F Gay and M Beksac and L Pantani and MT Petrucci and MA Dimopoulos and L Dozza and {van der Holt}, Ronnie and S Zweegman and S Oliva and {van der Velden}, Vincent and E Zamagni and GA Palumbo and F Patriarca and V Montefusco and M Galli and V Maisnar and B Gamberi and M Hansson and A Belotti and L Pour and P Ypma and M Grasso and A Croockewit and S Ballanti and M Offidani and ID Vincelli and R Zambello and AM Liberati and NF Andersen and A. Broijl and R Troia and A Pascarella and G Benevolo and MD Levin and G Bos and H Ludwig and S Aquino and AM Morelli and KL Wu and R Boersma and R Hajek and M Durian and {von dem Borne}, Pavd and {Caravita di Toritto}, T and T Zander and G Specchia and A Waage and P Gimsing and UH Mellqvist and {van Marwijk Kooy}, M and M Minnema and C Mandigers and AM Cafro and A Palmas and S Carvalho and A Spencer and M Boccadoro and Pieter Sonneveld",

year = "2020",

month = jun,

day = "1",

doi = "10.1016/s2352-3026(20)30099-5",

language = "English",

volume = "7",

pages = "E456--E468",

journal = "The Lancet Haematology",

issn = "2352-3026",

publisher = "Lancet Publishing Group",

number = "6",

}

Cavo, M, Gay, F, Beksac, M, Pantani, L, Petrucci, MT, Dimopoulos, MA, Dozza, L, van der Holt, R, Zweegman, S, Oliva, S, van der Velden, V, Zamagni, E, Palumbo, GA, Patriarca, F, Montefusco, V, Galli, M, Maisnar, V, Gamberi, B, Hansson, M, Belotti, A, Pour, L, Ypma, P, Grasso, M, Croockewit, A, Ballanti, S, Offidani, M, Vincelli, ID, Zambello, R, Liberati, AM, Andersen, NF, Broijl, A, Troia, R, Pascarella, A, Benevolo, G, Levin, MD, Bos, G, Ludwig, H, Aquino, S, Morelli, AM, Wu, KL, Boersma, R, Hajek, R, Durian, M, von dem Borne, P, Caravita di Toritto, T, Zander, T, Specchia, G, Waage, A, Gimsing, P, Mellqvist, UH, van Marwijk Kooy, M, Minnema, M, Mandigers, C, Cafro, AM, Palmas, A, Carvalho, S, Spencer, A, Boccadoro, M & Sonneveld, P 2020, 'Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study', The Lancet Haematology, vol. 7, no. 6, pp. E456-E468. https://doi.org/10.1016/s2352-3026(20)30099-5, https://doi.org/10.1016/S2352-3026(20)30099-5

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. / Cavo, M; Gay, F; Beksac, M et al.
In: The Lancet Haematology, Vol. 7, No. 6, 01.06.2020, p. E456-E468.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95)

T2 - a multicentre, randomised, open-label, phase 3 study

AU - Cavo, M

AU - Gay, F

AU - Beksac, M

AU - Pantani, L

AU - Petrucci, MT

AU - Dimopoulos, MA

AU - Dozza, L

AU - van der Holt, Ronnie

AU - Zweegman, S

AU - Oliva, S

AU - van der Velden, Vincent

AU - Zamagni, E

AU - Palumbo, GA

AU - Patriarca, F

AU - Montefusco, V

AU - Galli, M

AU - Maisnar, V

AU - Gamberi, B

AU - Hansson, M

AU - Belotti, A

AU - Pour, L

AU - Ypma, P

AU - Grasso, M

AU - Croockewit, A

AU - Ballanti, S

AU - Offidani, M

AU - Vincelli, ID

AU - Zambello, R

AU - Liberati, AM

AU - Andersen, NF

AU - Broijl, A.

AU - Troia, R

AU - Pascarella, A

AU - Benevolo, G

AU - Levin, MD

AU - Bos, G

AU - Ludwig, H

AU - Aquino, S

AU - Morelli, AM

AU - Wu, KL

AU - Boersma, R

AU - Hajek, R

AU - Durian, M

AU - von dem Borne, Pavd

AU - Caravita di Toritto, T

AU - Zander, T

AU - Specchia, G

AU - Waage, A

AU - Gimsing, P

AU - Mellqvist, UH

AU - van Marwijk Kooy, M

AU - Minnema, M

AU - Mandigers, C

AU - Cafro, AM

AU - Palmas, A

AU - Carvalho, S

AU - Spencer, A

AU - Boccadoro, M

AU - Sonneveld, Pieter

PY - 2020/6/1

Y1 - 2020/6/1

U2 - 10.1016/s2352-3026(20)30099-5

DO - 10.1016/s2352-3026(20)30099-5

M3 - Article

SN - 2352-3026

VL - 7

SP - E456-E468

JO - The Lancet Haematology

JF - The Lancet Haematology

IS - 6

ER -

Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. The Lancet Haematology. 2020 Jun 1;7(6):E456-E468. doi: 10.1016/s2352-3026(20)30099-5, 10.1016/S2352-3026(20)30099-5